Table 1 VAV3 nuclear and cytoplasmic expression in relation to other tumor markers assessed by the Spearman’s rank correlation a
From: VAV3 mediates resistance to breast cancer endocrine therapy
| Â | Nuclear VAV3, n(%) | Cytoplasmic VAV3, n(%) | ||||||
|---|---|---|---|---|---|---|---|---|
Score | – | 1+ | 2+ | 3+ | – | 1+ | 2+ | 3+ |
All tumors | 607 (85.9) | 3 (0.4) | 43 (6.1) | 54 (7.6) | 229 (32.4) | 154 (21.8) | 215 (30.4) | 109 (15.4) |
Tumor size (>20 mm vs. ≤20 mm) | Rs = −0.04, P = 0.30 | Rs = 0.13, P = 0.0009 | ||||||
Tumor grade (1, 2 or 3) | Rs = −0.09, P = 0.026 | Rs = 0.16, P = 0.00007 | ||||||
ERα (>10% vs. ≤10%) | Rs = 0.05, P = 0.20 | Rs = −0.12, P = 0.002 | ||||||
PR (>10% vs. ≤10%) | Rs = 0.06, P = 0.14 | Rs = −0.15, P = 0.0002 | ||||||
HER2 status (positive vs. negative) | Rs = 0.00, P = 0.99 | Rs = 0.05, P = 0.16 | ||||||
Phospho-Ser167 ERα (%) | Rs = 0.12, P = 0.002 | Rs = −0.11, P = 0.003 | ||||||
Phospho-Ser305 ERα (%) | Rs = 0.11, P = 0.006 | Rs = −0.09, P = 0.016 | ||||||
PAK1 (cytoplasm 0 to 3 positivity) | Rs = −0.07, P = 0.077 | Rs = 0.12, P = 0.003 | ||||||
Phospho-Ser473 AKT (nuclear %) | Rs = 0.18, P < 0.00001 | Rs = −0.20, P < 0.00001 | ||||||
Phospho-Ser2448 mTOR (high vs. low) | Rs = 0.06, P = 0.11 | Rs = −0.08, P = 0.034 | ||||||
Phospho-Ser65 4EBP1 (cytoplasm 0 to 2 positivity) | Rs = −0.15, P = 0.0001 | Rs = 0.19, P < 0.00001 | ||||||
S6K2 (nuclear %) | Rs = 0.21, P < 0.00001 | Rs = −0.26, P < 0.00001 | ||||||